NCT04621201 is a clinical trial of observation and biopsy in Diagnosed or Relapsed/Refractory Sarcomas, sponsored by Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna.

Who is sponsoring NCT04621201?

NCT04621201 is sponsored by Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna.

What drugs are being tested in NCT04621201?

Interventions in NCT04621201: observation and biopsy.

What condition does NCT04621201 study?

NCT04621201 studies Diagnosed or Relapsed/Refractory Sarcomas.

Is NCT04621201 still recruiting?

NCT04621201 is currently recruiting now. Last updated 29 March 2023.

Last reviewed 2023-03-29 · How we verify

NCT04621201

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas

Recruiting now Last updated 29 March 2023

What this trial tests

trial testing observation and biopsy in Diagnosed or Relapsed/Refractory Sarcomas in 120 participants. Currently enrolling.

Timeline

6 December 2018

Primary endpoint
6 December 2024

6 December 2026

Quick facts

Lead sponsor	Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	120
Start date	6 December 2018
Primary completion	6 December 2024
Estimated completion	6 December 2026
Sites	10 locations across Italy

Drugs / interventions tested

observation and biopsy

Conditions studied

Diagnosed or Relapsed/Refractory Sarcomas — all drugs for Diagnosed or Relapsed/Refractory Sarcomas →

Sponsor

Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna

Who can join

Under 24, any sex, with Diagnosed or Relapsed/Refractory Sarcomas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bone and soft tissue sarcomas represent about 7-12% of all pediatric cancer and are a heterogeneous group of tumors arising in connective tissues embryologically derived from the mesenchyme. For some of these tumors relapse and mortality rates are still significantly high. Therefore, further studies are needed to better understand pathogenetic processes underlying sarcomas to offer new and more effective treatments. Next generation sequencing (NGS) has opened new frontiers for cancer research allowing to identify somatic or constitutional mutations known or yet unknown with the aim to better understand carcinogenesis. The establishment of the genomic profile of the tumor could also help clinicians to personalize patients treatment based on their genetic and molecular alterations.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Impaired neutrophil-mediated cell death drives Ewing's Sarcoma in the background of Down syndrome.
Peirone S, Tirtei E, Campello A, Parlato C, et al · · 2024 · cited 1× · PMID 39421445 · DOI 10.3389/fonc.2024.1429833
Mapping Genomic Heterogeneity in Pediatric and Adolescent-Young Adult Sarcomas: Insights from the Italian SAR-GEN2016 and SAR-GEN_ITA Prospective Multicenter Trials.
Tirtei E, Difilippo V, Divincenzo F, Asaftei SD, et al · · 2026 · PMID 41880642 · DOI 10.1158/2767-9764.crc-25-0697

Verify or expand the search:

Other Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna trials

Trials by the same sponsor.

NCT05531721 — HLH Patients - a Retrospective Study · completed
NCT07372690 — Goal Attainment Scale in Transplantation · NA · recruiting
NCT04651569 — An Analysis of the Efficacy of High Dose Isofosfamide Through Elastomer · completed
NCT04598789 — A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors · completed
NCT04651179 — Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04621201 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Last refreshed: 29 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04621201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing